ࡱ> JLI /bjbj$$ ;4F|F| (((<<<8t\<'"D0000=X!!!!!!!$ $&!(AAA!00!A(0(0!A!* v 0psdB !!0'"J ,=''~='v ='(v AAAAAAA!!AAA'"AAAA='AAAAAAAAA :  FORMTEXT , MD  FORMTEXT    FORMTEXT 
  FORMTEXT 
  FORMTEXT ,  FORMTEXT   FORMTEXT   FORMTEXT   FORMTEXT   FORMTEXT   FORMTEXT 
  FORMTEXT 
  FORMTEXT ,  FORMTEXT    FORMTEXT  Re:  FORMTEXT  DOB:  FORMTEXT  Member ID:  FORMTEXT  Group ID:  FORMTEXT  Dear Medical Director: I am writing this letter on behalf of my patient  FORMTEXT  to request coverage for additional testing for Peripheral Neuropathy. This letter documents the medical necessity for autoimmune antibody testing to establish a specific diagnosis and provides information about the patients medical history and treatment. As you know, peripheral neuropathy refers to a group of disorders that present with damage to the peripheral nervous system. Unfortunately, there are more than 100 different types of peripheral neuropathy due to a variety of causes. Acquired neuropathies can be caused by systemic diseases, toxins, infections or autoimmune disorders, but it is often difficult to determine an exact etiology as it is not apparent from routine testing. In fact, in up to 50% of cases, the cause of neuropathy remains elusive even after a thorough clinical work up. In these cases, autoimmune antibody testing offers the additional means to pinpoint the precise cause of this disorder. Patient History and Diagnosis:  FORMTEXT  is a  FORMTEXT   year old  FORMTEXT  with a suspected diagnosis of peripheral neuropathy due to the following symptoms and clinical findings. 1.  FORMTEXT  2.  FORMTEXT  3.  FORMTEXT  4.  FORMTEXT  These symptoms suggest that an autoimmune peripheral neuropathy is still part of the differential diagnosis and immune testing is the only way to test this possibility and treat the patient appropriately. Athena Diagnostics autoimmune antibody testing provides the following benefits to the patient: An accurate diagnosis for prognostic information. Presents appropriate immune treatment options. Avoid treatment by excluding some forms of immune neuropathy like CIDP. Initiates treatment early in the course of disease progression which may allow the patient to improve their quality of life.1 I am requesting that  FORMTEXT  be approved for the SensoriMotor Neuropathy Profile Complete, PUC # 287 through Athena Diagnostics, Federal Tax ID #: 31-1805826 / NPI #: 1023063062 with the following CPT code(s): 83520(11). I am specifying Athena Diagnostics to perform the test as Athenas superior lab methodology, high specificity and sensitivity for antibodies causing peripheral neuropathy provide accurate results. The SensoriMotor Neuropathy Profile identifies the following antibodies: Co-GM1, Asialo-GM1, GD1a, GD1b, Mag, SGPG, Hu, GALOP, Sulfatide in its evaluation. I hope you will support this letter of medical necessity for  FORMTEXT . Please feel free to contact me at  FORMTEXT  if you have additional questions. Sincerely,  FORMTEXT , MD NPI #:  FORMTEXT       http://www.ninds.nih.gov/disorders/peripheralneuropathy/detail_peripheralneuropathy.htm, Aug. 2010-08-04  Kornberg, A.J. and Pestronk, A., Antibody -Associated Polyneuropathy Syndromes: Principals and Treatment Seminars in Neurology, Vol. 23, No. 2, 2003.    #$./0>?@AKLMXYZ[efg崬崬~scsPc$jhwh>B*Uphjhwh>B*Uphhwh4aB*phj>h>B*Uphh4aB*mHnHphujh>B*Uphh4aB*phjh>B*Uph hrh4aB*mHnHphu$jhrh>B*Uphhrh4aB*phjhrh>B*Uph#@Zt ) C ] ; < S T CDgd3_gd~\gd@gd4agrstuԮԛԐxmZx$jh#0h>B*Uphh#0h@B*phjh#0h>B*Uphh4aB*phh Uh4aB*ph$jThwh>B*Uph$jhwh>B*Uph$jRhwh>B*Uphhwh4aB*phjhwh>B*Uph hwh4aB*mHnHphu      ' ( ) * 4 5 6 A B C D N O P [ \ ] ^ h ǿǡǿԎ{h$jFh#0h>B*Uph$jh#0h>B*Uph$jh#0h>B*Uphh-B*mHnHphujRh-B*Uphh-B*phjh-B*Uphh#0h@B*phjh#0h>B*Uph h#0h@B*mHnHphu!h i j p q s t ~  }j$jh#0h>B*Uph$jTh#0h>B*Uphh#0h@B*ph$jh#0h>B*Uph$jTh#0h>B*Uphh#0h@B*ph h#0h@B*mHnHphujh#0h>B*Uph$jh#0h>B*Uph%       ' ( ) 9 : ; < S T |ujbRDjh$1B*mHnHphuj h>B*Uphh$1B*phh$1h~\B*ph h Uh~\ h Uh@h Uh@B*phh@B*mHnHphuj h>B*Uphjh>B*Uphh@B*phhh@B*ph h#0h@B*mHnHphujh#0h>B*Uph$j~ h#0h>B*Uph  $ - 1 4 8 W ! 5 H R p x   " , / 5 9 V X !)@ABCDcḏԪjh>B*Uphh Uh~\5 h Uh(^jht0JB*Uphh Zh3_B*phh(^B*phh~\B*phh/aB*phh$1h~\B*phhyaB*phh ZB*ph:Dc%jUV$%0gdW6h^hgdr & Fgd~\ & FgdHygd~\dnop~()345himnx|l^|h-B*mHnHphuj h-B*Uphh-B*phjh-B*Uphh`W'B*phh{B*phjR h>B*Uphj h>B*Uphh,h~\B*phh,B*mHnHphujh>B*Uphj> h>B*Uphh,B*ph!xyz  STUVetu#9㽭㽝㒊wogoww_Wh{B*phhPNB*phh:B*phh`W'B*phh ZB*phh,h~\B*phh~\B*phh,hyaB*phjh-B*Uphjh-B*Uphh-B*phhyaB*phh~\B*phh-B*mHnHphujh-B*Uphj h-B*Uph 9DU -./079ouļܼļĬԝ̼̼̊}rejh>B*UphhTvh~\B*phhsMhsMB*H*phh]B*phh,h ZB*phjht0JB*UphhW6B*phhB*phhHyB*phh ZB*phh`W'B*phhPNB*phh~\B*phh,h~\B*phh{B*phh/aB*ph%*efBCMNO]^{tdj>h>B*Uph h Uh~\jh>B*Uphjh>B*UphhTvhW6B*phhW6hW6B*phhW6B*phhrB*phhTvh~\B*phhTvB*mHnHphujh>B*Uphjh>B*UphhTvB*ph'   !#$&'*+,-./ھ|h]hHy6]hHyhHymHsHh-hHymHsHhthHymHsHjhHy0JUhejheUh^jh>B*UphhTvB*phhTvh~\B*phjh>B*UphhTvB*mHnHphu "#%&()*-./ 91h:p ;0BP/ =!"#$% D2Text1<Physician Name> FIRST CAPITALDKText2<Institution> DdText3 <Address 1>DdText4 <Address 2>DKText5<City>D2Text6<State>~D Text7<ZIP>DText8<Date>DText45&<Medical Director/Physician Name, M.D>DText10<Insurance Company Name>D2Text11 <Address 1>D2Text12 <Address 2>D2Text13<City>DText14<ST> DText15<ZIP>DKText16<Patient Full Name>DText17 <MM/DD/YYYY>DText18<Enter Member ID>DText19<Enter Group ID>D2Text20<Patient Name>D2Text23<Patient Name>DText24<Age> D Text25 <Gender >DText463<E.g. Weakness in legs and then arms, ICD-9 code: >DText47<<E.g. Loss of sensation in legs and then arms, ICD-9 code: >DText48<<E.g. Slow degeneration of peripheral muscles, ICD-9 code: >DText49=<E.g. Burning sensation in hands and then feet, ICD-9 code: >D2Text36<Patient Name>D2Text41<Patient Name>D(Text42<Physician Phone>DKText43<Physician Name>D(Text44<Physician NPI#>j 2 0@P`p2( 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p 0@P`p8XV~ OJPJQJ_HmH nH sH tH L`L ~\Normal$CJOJPJQJ_HaJmH sH tH DA`D Default Paragraph FontRiR 0 Table Normal4 l4a (k ( 0No List BB ~\0Placeholder Text B*phH@H ~\0 Balloon TextCJOJQJ^JaJRR ~\0Balloon Text CharCJOJPJQJ^JaJ>@"> ] Footnote TextCJaJ@&1@ ]Footnote ReferenceH*<+@B< t Endnote TextCJaJ>*@Q> tEndnote ReferenceH*6Ua6 t Hyperlink >*B*phPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭V$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3N)cbJ uV4(Tn 7_?m-ٛ{UBwznʜ"Z xJZp; {/<P;,)''KQk5qpN8KGbe Sd̛\17 pa>SR! 3K4'+rzQ TTIIvt]Kc⫲K#v5+|D~O@%\w_nN[L9KqgVhn R!y+Un;*&/HrT >>\ t=.Tġ S; Z~!P9giCڧ!# B,;X=ۻ,I2UWV9$lk=Aj;{AP79|s*Y;̠[MCۿhf]o{oY=1kyVV5E8Vk+֜\80X4D)!!?*|fv u"xA@T_q64)kڬuV7 t '%;i9s9x,ڎ-45xd8?ǘd/Y|t &LILJ`& -Gt/PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!0C)theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] @. /k/4 gh dx9/ D/  #/>@LXZfrt')5ACO[]ips(9co~(4hmy S B N ] /FFFFFFFFFTFFFFFFFFFFFFFFFTFTFTFTFFFFFL# @0(  B S  ?Text1Text2Text3Text4Text5Text6Text7Text45Text20Text23Text24Text25Text46Text47Text48Text49Text36Text41Text42Text43Text44#@Ztc(m  B 0 ?YsSiT ^ 0  l x  "#%&(*,z-0  "#%&(*,033#?@YZst()BC\]qs:c(im T B ^ 0R8fG ^`OJQJo(^`OJQJ^Jo(o pp^p`OJQJo( @ @ ^@ `OJQJo(^`OJQJ^Jo(o ^`OJQJo( ^`OJQJo(^`OJQJ^Jo(o PP^P`OJQJo(R8         AcM" 5 Tv{pnx Zov `W'x*-$1X5W6>bFsM(^3_/a4aya@e|?h?k89lJl_uw_GyO?t @Q'g+H:, r$mhr^y|L*Hy~\e;".PNY]R@  /@UnknownG*Ax Times New Roman5Symbol3. *Cx Arial7.@ Calibri5. .[`)Tahoma?= *Cx Courier New;WingdingsA$BCambria MathBqh5,Ǯ5,ǙrF A !203KX  $Px*2!xx <Physician Name>, MD Paul Lizotte Joseph Sterk Oh+'0d    , 8DLT\, MDPaul LizotteNormalJoseph Sterk2Microsoft Office Word@@ T@P@P ՜.+,0  hp  Quest Diagnostics , MD Title  !"#$&'()*+,-./012345678:;<=>?@BCDEFGHKRoot Entry F0sMData j1Table%M'WordDocument;4SummaryInformation(9DocumentSummaryInformation8ACompObjr  F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q